Ghrelin Administration Dose-Dependently Increases Plasma Oxytocin Release in Rats via the Ghrelin System
Background
The hypothalamic-pituitary axis is a critical regulator of metabolic homeostasis, secreting neuropeptides that maintain balance. Within this system, the neuropeptide oxytocin has emerged as a potential therapeutic target for obesity and related metabolic disorders. Understanding the factors that control oxytocin secretion is therefore crucial for developing new treatments. This study investigates the potential influence of the ghrelin system, a key player in hunger and metabolism, on oxytocin release, exploring a novel metabolic pathway that could be leveraged for therapeutic intervention.
Study Design
Researchers investigated ghrelin-induced oxytocin secretion in rats. Ghrelin was administered either centrally via intracerebroventricular (i.c.v.) injection at doses of 1.0, 10.0, and 100.0 pmol, or systemically via intravenous (i.v.) injection at doses of 1.0 and 10.0 nmol. In a separate arm, the ghrelin antagonist [d-Lys³]-GHRP-6 was injected 15 minutes before ghrelin administration, at a dose of 10.0 pmol i.c.v. or 10.0 nmol i.v., to confirm the mechanism of action. Plasma oxytocin concentration was the primary endpoint measured.
Results
Both central (i.c.v.) and systemic (i.v.) administration of ghrelin resulted in a dose-dependent increase in plasma oxytocin concentration. This demonstrates that ghrelin can stimulate oxytocin release through actions both within the brain and in the periphery. The mechanism was confirmed to be specific to the ghrelin system.
Following pretreatment with the ghrelin antagonist [d-Lys³]-GHRP-6, the high plasma oxytocin level induced by ghrelin was significantly reduced. This blockade by the antagonist confirms that the observed increase in oxytocin is directly mediated by ghrelin receptor activation. The results clearly establish a direct and influential link between the ghrelin system and the regulation of oxytocin release, highlighting a previously uncharacterized neuroendocrine connection.
Key Findings
- Both central (i.c.v.) and systemic (i.v.) ghrelin administration dose-dependently increased plasma oxytocin levels in rats.
- Pretreatment with the ghrelin antagonist [d-Lys³]-GHRP-6 significantly reduced the ghrelin-induced rise in plasma oxytocin.
- The results indicate that the release of oxytocin is directly influenced by the ghrelin system.
Why It Matters
The study reveals a direct regulatory link where ghrelin stimulates oxytocin, a peptide with known metabolic benefits. This suggests that interventions targeting the ghrelin system could be used to modulate oxytocin levels for therapeutic purposes, particularly in the context of obesity and metabolic disorders. For individuals using ghrelin-releasing peptides (GHRPs), this finding implies an additional, previously unrecognized effect on oxytocin, which could influence appetite, social bonding, and metabolic rate. Understanding this ghrelin-oxytocin axis opens a new horizon for developing novel therapeutic strategies that leverage this interaction. Further research is needed to translate these findings from rats to human clinical protocols and determine the practical implications for dosing and stacking peptides.
